Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10416–10418.

https://doi.org/10.1182/blood-2022-159595

Published: 2022

Journal Articles

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Susan O'Brien, Loretta J. Nastoupil, James Essell, Ly Dsouza, Doug Hart, Emiri Matsuda, Tarah Satterfield, Tonia Nesheiwat, Ashley Hammad, Franco Davi, Shally Chung, S. Asim Shamsi, Mara Bryan, Justin Skoble, Elizabeth Garner, Steven Kanner, Syed Rizvi, Houston Holmes

Blood (2022) 140 (Supplement 1): 9457–9458.

https://doi.org/10.1182/blood-2022-168128

Published: 2022

Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy

Blood (2021) 138 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2021-148792

Published: 2021

Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-136640

Published: 2020

Journal Articles

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Madan Jagasia, MBBS, MS, MMHC, Amandeep Salhotra, MD, Carlos R. Bachier, MD, Behyar Zoghi, MD, PhD, FACP, Aleksandr Lazaryan, MDPhDMPH, Daniel J. Weisdorf, MD, James Essell, MD, Laurie S. Green, MD, Olivier Schueller, PhD, Lindy Huang, Zhongming Yang, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, MD, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2019) 134 (Supplement_1): 872.

https://doi.org/10.1182/blood-2019-125986

Published: 2019

Journal Articles

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Madan Jagasia, MD MS, Amandeep Salhotra, MD, Carlos R. Bachier, MD, James Essell, MD, Daniel J. Weisdorf, MD, Behyar Zoghi, MD PhD, Laurie S. Green, MD, Olivier Schueller, PhD, Alexandra Zanin-Zhorov, PhD, Jonathan M. Weiss, PhD, David Eiznhamer, PhD, Sanjay K. Aggarwal, Bruce R. Blazar, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 602.

https://doi.org/10.1182/blood-2018-99-111896

Published: 2018

Journal Articles

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Matthew S. Davids, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, James Essell, MD, Nicole Lamanna, MD, Zsolt Nagy, MD PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Stephan Stilgenbauer, Paolo Ghia, MD PhD, Julio Delgado, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Ulrich Jaeger, MD

Blood (2018) 132 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2018-99-117521

Published: 2018

Journal Articles

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Richard T. Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Chris Storgard, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 2167.

https://doi.org/10.1182/blood-2018-99-115088

Published: 2018

Journal Articles

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

Ilana Schlam, MD, Samantha Buszek*, MD, James Essell

Blood (2017) 130 (Supplement 1): 5508.

https://doi.org/10.1182/blood.V130.Suppl_1.5508.5508

Published: 2017

Journal Articles

Initial Results of KD025-208: A Phase 2a Open Label Trial of KD025 for Steroid-Dependent Chronic Graft Versus Host Disease

Aleksandr Lazaryan, MD PhD MPH, Stephanie J Lee, MD MPH, Amandeep Salhotra, MD, Madan Jagasia, MD MBBS, MS, James Essell, MD, Alexandra Zanin-Zhorov, PhD, Beth Mac Gillivray, MSc, Olivier Schueller, PhD, David Eiznhamer, PhD, Bruce Blazar, MD, John L. Ryan, MD PhD

Blood (2017) 130 (Supplement 1): 3256.

https://doi.org/10.1182/blood.V130.Suppl_1.3256.3256

Published: 2017

Journal Articles

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Ilana Schlam, MD, Samantha Buszek*, MD, Matan R Rothschild, MD, Miguel Islas-Ohlmayer, MD, James Essell

Blood (2017) 130 (Supplement 1): 5493.

https://doi.org/10.1182/blood.V130.Suppl_1.5493.5493

Published: 2017

Journal Articles

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Richard Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, MD, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Daniel Fremgen, Chris Storgard, MD, Abhinav Deol, MD

Blood (2017) 130 (Supplement 1): 4498.

https://doi.org/10.1182/blood.V130.Suppl_1.4498.4498

Published: 2017

Journal Articles

Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat

Blood (2016) 128 (22): 1166.

https://doi.org/10.1182/blood.V128.22.1166.1166

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 901.

https://doi.org/10.1182/blood.V128.22.901.901

Published: 2016

Journal Articles

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Jesus G. Berdeja, MD, Rami S. Komrokji, MD, James Essell, MD, Roger M. Lyons, MD, Michael Maris, MD, Amy E. DeZern, MD MHS, Mikkael A. Sekeres, MD MS, Gail J Roboz, MD

Blood (2015) 126 (23): 911.

https://doi.org/10.1182/blood.V126.23.911.911

Published: 2015

Journal Articles

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

William B. Donnellan, MD, Jesus Berdeja, MD, Dianna Shipley, MD, Edward Arrowsmith, MD MPH, David Wright, MD, Scott Lunin, MD, Richard H. Brown, MD, James Essell, MD, Ian Flinn

Blood (2014) 124 (21): 3336.

https://doi.org/10.1182/blood.V124.21.3336.3336

Published: 2014

Journal Articles

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Jesus Berdeja, MD, Michael Savona, MD, Joseph R Mace, MD, Lowell Hart, MD, James Essell, MD, Rami Owera, MD, Edward Arrowsmith, MD, MPH, Ian Flinn, MD, PhD

Blood (2013) 122 (21): 1937.

https://doi.org/10.1182/blood.V122.21.1937.1937

Published: 2013

Journal Articles

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Ruben Niesvizky, MD, Ian Flinn, MD, PhD, Robert M. Rifkin, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas Warr, MD, Rachel Neuwirth, Ph.D, Abbie Ba-Mancini, BS MBA, Yanyan Zhu, Ph.D, MPH, Liviu Niculescu, MD, James Reeves, MD

Blood (2013) 122 (21): 1966.

https://doi.org/10.1182/blood.V122.21.1966.1966

Published: 2013

NARROW

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 Data

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

Initial Results of KD025-208: A Phase 2a Open Label Trial of KD025 for Steroid-Dependent Chronic Graft Versus Host Disease

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM)

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only